BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 19, 2009
View Archived Issues
Novel cytochrome P450 inhibitors in early development at Gilead
Read More
Bial Portela discloses FAAH inhibitors for the treatment of pain and other conditions
Read More
Vertex presents new JAK2 inhibitors for treatment of myeloproliferative disorders
Read More
Alios BioPharma describes RNAseL inhibitors in early development
Read More
Novel checkpoint kinase inhibitors claimed by DCB-USA
Read More
Schering-Plough claims GR agonists for the treatment of allergic and inflammatory conditions
Read More
Ligand patent covers novel SARMs for treatment of musculoskeletal and other disorders
Read More
Amgen reports results for second quarter 2009
Read More
BioSante reports LibiGel safety data from phase III program
Read More
Meda launches Edluar in the U.S.
Read More
GlaxoSmithKline and Genmab report results from Arzerra study in NHL
Read More
Immunomedics obtains FDA approval to initiate phase I/II myeloma study
Read More
Crucell receives NIH award for development of influenza monoclonal antibodies
Read More
GlycoMimetics receives grant to study E-selectin small molecule antagonists
Read More
Vectibix improved progression-free survival in phase III colorectal cancer trial
Read More
Mount Sinai added as site for phase II PH-10 trial for psoriasis
Read More
Neuropeptide S receptor antagonists developed at Merck & Co.
Read More
Phase I data describe MP-470 plus chemotherapy in SCLC and neuroendocrine tumors
Read More
OSI Pharmaceuticals describes discovery of oncolytic agent OSI-906
Read More
Thrombin inhibitors FM-19 and TH-146 have anticancer activity
Read More
GSK works toward oral calcium-sensing receptor antagonists for osteoporosis
Read More
Almirall develops antedrug PDE4 inhibitors for psoriasis
Read More
Lilly reports results from phase III GJAD GENERATIONS trial of arzoxifene
Read More
FDA accepts for review BioAlliance's NDA for Lauriad for OPC
Read More